Monthly migraine days (MMD)
Neurology· appears in 277+ cited findings in this library
What it is and how the reviews use it
Monthly migraine days (MMD) is an endpoint used in regulatory review documents to quantify the frequency of migraine headaches experienced by patients. It measures the number of days in a month that a patient experiences a migraine. The FDA review for AbbVie Inc.'s Atogepant (NDA215206, ORIG 1, 2021, p.23) defines a reduction in mean monthly migraine days as ranging from 0.7 to 1.7 days.
Regulatory reviews frequently use MMD to assess the efficacy of new treatments. For instance, the H. Lundbeck A/S Vyepti FDA Review (BLA761119, ORIG 1, 2020, p.58) reported a mean change from baseline in monthly migraine days of -4.3. Similarly, the Eli Lilly and Company Emgality FDA Review (BLA761063, ORIG 1, 2018, p.194) noted a reduction in monthly migraine days of 4-5 days. The Novartis AG Aimovig EMA EPAR public assessment report (EMEA/H/C/0044, p.58) presented a common odds ratio for >=50% reduction in monthly migraine days vs placebo of 1.74.
Real examples — cited to the source page
| Novartis AG — Aimovig | Common odds ratio for >=50% reduction in monthly migraine days vs placebo | 1.74 | Aimovig EMA EPAR, p.58 |
| H. Lundbeck A/S — Vyepti | Mean change from baseline in monthly migraine days | -4.3 | Vyepti FDA Review, p.58 |
| AbbVie Inc. — Atogepant | Number of monthly migraine days observations for exposure-response analysis | 6471 | Atogepant FDA Review, p.183 |
| Eli Lilly and Company — Emgality | Reduction in monthly migraine days | 4-5 | Emgality FDA Review, p.194 |
| Fulcrum Therapeutics, Inc. — Bocunebart | Bocunebart MMD reduction vs placebo | -2.3 | SEC 8-K, p.15 |
| AbbVie Inc. — Aquipta | Adjusted p-value for atogepant 30 mg QD vs. placebo for monthly migraine days | <.0001 | Aquipta EMA EPAR, p.81 |
| Teva Pharmaceutical Industries Limited — Ajovy | Reduction in monthly migraine days or moderate to severe headache days compared to placebo | 2 | Ajovy FDA Review, p.155 |
| Pfizer Inc. — Vydura | Net difference in monthly migraine days (MDs) vs placebo | -1.2 | Vydura EMA EPAR, p.94 |
Different drugs were studied in different trials — these values are not head-to-head comparisons.
Explore the full evidence
Every Monthly finding in the library — searchable and answerable in plain language — is in the Neurology research library →
Figures are as stated in the cited source documents. Educational reference only — not medical or investment advice.